2019 was another big year for cancer research. As editors of the Cancer Currents blog, one of our goals is to report on news of interest to the cancer community and capture a slice of the diverse nature of cancer research today, especially that funded by NCI. Our most-read posts of the year reflect that diversity.
Although immunotherapy continues to be an area of intense interest, advances in other areas—from exploiting cancer cell metabolism to understanding and addressing cancer disparities—were clearly on our readers' radars.
So, in case you missed them when they were first published or want to read them again or share them with a friend, here are our most-read posts of 2019.
Thanks for your interest in and support of Cancer Currents. If you like what you're reading, please share our content with friends and colleagues and encourage them to subscribe.
Updated guidelines on exercise for those living with cancer and cancer survivors were recently released. In this conversation, Dr. Kathryn Schmitz discusses what these new guidelines mean for doctors, patients, and survivors.
The expanding use of cancer immunotherapy has revealed a variety of side effects associated with this treatment approach. Researchers are now trying to better understand how and why these side effects occur and develop strategies for better managing them.
Findings from an NCI-funded study suggest a new vaccine approach may have the potential to prevent colorectal cancer in people with Lynch syndrome, an inherited condition that increases an individual's risk for developing certain types of cancer.
FDA has approved atezolizumab (Tecentriq) in combination with chemotherapy for the treatment of some women with advanced triple-negative breast cancer. This is the first FDA-approved regimen for breast cancer to include immunotherapy.
Researchers have engineered an oncolytic virus to kill cancer cells and boost the immune response against tumors. In a new study, the virus provided T cells around tumors with a hormone they need for their own cell-killing functions.
For African American men, the risk of dying from low-grade prostate cancer is double that of men of other races, a new study has found. But, despite the difference, the risk is still small.
A new study has identified a potential biomarker of early-stage non-small cell lung cancer (NSCLC). The biomarker, the study's leaders said, could help diagnose precancerous lung growths and early-stage lung cancers noninvasively and distinguish them from noncancerous growths.
An NCI-funded clinical trial is testing the immunotherapy drug nivolumab (Opdivo) in people who have advanced cancer and an autoimmune disease—such as rheumatoid arthritis, lupus, or multiple sclerosis—who are often excluded from such trials.
A new NCI-supported study showed that altering cancer cell metabolism by feeding mice a diet very low in the nutrient methionine improved the ability of chemotherapy and radiation therapy to shrink tumors.
Men and women with glioblastoma appear to respond differently to standard treatment. A new study identifies biological factors that might contribute to this sex difference.
This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892
No comments:
Post a Comment